Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02898519
Other study ID # 2015/CHU/07
Secondary ID
Status Not yet recruiting
Phase N/A
First received September 8, 2016
Last updated September 8, 2016
Start date October 2016
Est. completion date September 2018

Study information

Verified date September 2016
Source Centre Hospitalier Universitaire de la Réunion
Contact CHRISTINE JUHEL, PHD
Phone +262262359949
Email christine.juhel@chu-reunion.fr
Is FDA regulated No
Health authority France: The Commission nationale de l’informatique et des libertésFrance: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé
Study type Observational

Clinical Trial Summary

Leptospirosis is a zoonotic infection induced by pathogen bacteria (genus: Leptospira) growing in water polluted by animal fluids. Due to its 10 fold occurence in French overseas aera, and especially in Reunion Island, as compared to metropoly, it is considered as a major public health issue.

An important inter-individual variability in humoral immune response suggests that vaccination should be recommended in exposed subjects.

This cohort study aimed to determine if subjects that have been infected by leptospirosis for 1 to 7 years still remain immunized, and then do not need vaccination.


Description:

Every year more than 500 000 severe forms of leptospirosis are diagnosed in Reunion Island. The risk of mucocutaneous contact with contaminated media remains important due to highly aqueous environment.

Cured subjects that have been infected for 1, 2, 3, 4, 5, 6 or 7 years will be enrolled. The qualitative and quantitative humoral immune response to leptospirosis infection will also be evaluated to determine whether they still get protective immunization. Leptospirosis immunization will be evaluated using micro-agglutination test.

Graded immune responses related to the severity and the length of the infection will also be investigated.

Finally, 3 methods used for leptospirosis diagnosis will be compared. It is expected from this study to evaluate the appropriate conditions in which new vaccination could be required to prevent further leptospirosis infection in cured subjects.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 175
Est. completion date September 2018
Est. primary completion date December 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects diagnosed for leptospirosis by polymerase chain reaction measured in Reunion Island Hospital between 209-2015

- with social security issue

Exclusion Criteria:

- Leptospirosis diagnosis not confirmed by polymerase chain reaction

- subject exhibiting immunodepressive status (cancers, transplantation, immune deficit, blood disorders)

- under medication: corticoids, immunosuppressor, chemiotherapy

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Other:
cohort
Blood sampling

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de la Réunion Institut Pasteur

Outcome

Type Measure Description Time frame Safety issue
Primary Leptospirosis immunization assessed by serum immunoglobulin Humoral immune response will be measured in serum cured-subjects using micro-agglutination test 1-7 years after leptospirosis infection No
Secondary rate of still-immunized patients Seropositive subjects will be measured using the ELISA serion method and the ELISA recombinant protein method 1-7 years after leptospirosis infection No
Secondary comparison of 3 diagnosis method for leptospirosis Matched results of the 3 methods: micro-agglutination test, ELISA serion method and ELISA recombinant protein method will be compared 1-7 years after leptospirosis infection No
See also
  Status Clinical Trial Phase
Recruiting NCT05425524 - Leptospirosis Care Bundle Study N/A
Completed NCT03912506 - Severe Leptospirosis in Non-tropical Areas
Recruiting NCT04288674 - Leptospirosis Registry - LeptoScope
Recruiting NCT05300425 - Seroprevalence of Leptospirosis in Val Müstair, Switzerland
Completed NCT01080989 - The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands N/A
Recruiting NCT05436756 - Chronic Post-leptospirosis Manifestations in Reunion N/A
Recruiting NCT04882046 - Study of the Incidence of Jarisch-Herxheimer Reaction in Leptospirosis Patients in New Caledonia N/A
Terminated NCT00592566 - Desmopressin and Dexamethasone Adjunctive Treatment for Leptospirosis Phase 2/Phase 3
Recruiting NCT04034550 - Cohort of Hospitalized Patients Suspected of Leptospirosis N/A
Completed NCT05413720 - Study of the Innate Immune Response to the Acute Phase of Human Leptospirosis - IMMUNOLEPTO N/A
Completed NCT01766830 - Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) N/A
Recruiting NCT02000635 - Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique
Active, not recruiting NCT01607047 - French West Indies Leptospirosis Study
Completed NCT03497572 - Seroprevalence Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine